Anticoagulation et fragilité osseuse : quelles implications pour la pratique clinique ? [Anticoagulant and bone fragility: which implications for clinical practice?]
Details
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_A7DBE0CB1C53
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Anticoagulation et fragilité osseuse : quelles implications pour la pratique clinique ? [Anticoagulant and bone fragility: which implications for clinical practice?]
Journal
Revue medicale suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
21/04/2021
Peer-reviewed
Oui
Volume
17
Number
735
Pages
766-769
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
The role of certain treatments in the development of bone fragility is well known. Since the 2000s, several studies, conducted in patients on long-term anticoagulants have suggested the involvement of vitamin K antagonist (VKA) in the occurrence of osteoporotic fractures. Since their launch in 2008, the new oral anticoagulants (NOACs) have been widely used. Compared to VKA, this drugs' class is associated with a lower fracture risk. Therefore, the presence of risk factors for fracture should be considered when prescribing long-term anticoagulants. In this line, the NOACs seem to be an interesting alternative for patients at risk of fracture requiring a long-term anticoagulation. Nevertheless, certain aspects remain to be clarified.
Keywords
Administration, Oral, Anticoagulants/adverse effects, Atrial Fibrillation/drug therapy, Humans, Osteoporotic Fractures/epidemiology, Osteoporotic Fractures/prevention & control, Risk Factors, Stroke, Vitamin K/therapeutic use
Pubmed
Create date
11/05/2021 10:50
Last modification date
30/12/2023 8:16